SVSimon Vandekar

Simon Vandekar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Vandekar has a total of 611 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contributions of Site Heterogeneity in Multi-site Brain-Phenotype Predictions

    by Guanru Chen, Megan Jones, Ishaan Gadiyar, Theodore D. Satterthwaite, Andrew Chen, Simon Vandekar

    Machine learning studies of brain–phenotype associations typically summarize accuracy with a single Pearson correlation, yet in harmonized multi-site data this metric is shaped by training-set size, feature and outcome variability, and true effect heterogeneity. We analyzed structural MRI data from the Reproducible Brain Charts consortium. After preprocessing and quality control, 3486 participants from 9 sites were retained. Three training set compositions were used to understand contributions of site heterogeneity after harmonization: within-site (Local), size-downsampled multi-site (Multi-Down), and full multi-site (Multi-Full). Another site-agnostic strategy (Overall) pooled all sites into a single dataset. All strategies included the target site in the training and testing samples. These analyses separate the contribution of the site effect from that of sample size. Between-site heterogeneity was extensive (age I ² ≈ 95%). The overall correlation of age prediction ( r = 0.73) exceeded the within-site meta-analytic estimate (Multi-Full r = 0.63). The improvement of correlation in the pooled dataset was driven by a mechanical inflation from the larger outcome variance. At matched sample size, within-site training outperformed harmonized multi-site training. Increasing the multi-site training sample size did not yield a significant advantage over within-site training. The apparent advantage of cross-dataset training thus appears to reflect training-set size rather than a benefit of multi-site composition per se. The same pattern generally held for the weaker brain-p-factor signals. Together, these results indicate that between-site heterogeneity in machine learning brain– phenotype prediction persists after harmonization. We recommend reporting site-level prediction accuracy and feature dispersion and standard deviation of the outcome variable alongside any pooled estimate to improve inter-site and inter-study comparison of machine learning prediction accuracy. Key points: Between-site heterogeneity in machine-learning brain–phenotype prediction persists after harmonization: across nine CovBat-harmonized sites ( N = 3,486), within-site models outperformed multi-site models at matched training size, and enlarging the multi-site training set did not consistently surpass within-site training. A single pooled correlation masks this heterogeneity: pooling sites overstated within-site accuracy for age ( r = 0.73 vs. 0.63), largely because pooling widens the outcome’s range. Site-level accuracy tracked imaging-feature variance and outcome variability; we recommend reporting site-level accuracy, feature variance, and outcome standard deviation alongside any pooled estimate.

  • Open Access

    Facilitating Valid Statistical Inference in Biomedical Image Synthesis

    by Jiangmei Xiong, Shunxing Bao, Qi Liu, Ken S. Lau, Lori A. Coburn, Keith T. Wilson, Bennett A. Landman, Simon Vandekar, Siyuan Ma

    Generative AI for medical image synthesis is increasingly used to impute missing data and augment biomedical datasets. Yet despite achieving high computational similarity to their real-world counterparts, synthetic images remain uncommon in clinical research practice, in part because of concerns about their biological validity. Here, we evaluate whether synthetic images support reliable downstream statistical analysis and biological inference in magnetic resonance imaging (MRI) and multiplexed immunofluorescence (mIF) imaging. We find that associations between patient phenotypes and synthesized images can be severely attenuated. This is because synthesis methods typically omit clinically relevant covariates and therefore generate images that, although visually realistic, mask key biological differences. Furthermore, naive analyses treat synthesized images as if they were observed, ignoring the statistical uncertainty introduced by synthesis. Drawing on multiple imputation theory, we introduce Phenotype Aware Multiple Synthesis (PAMS), an analysis framework that requires no model retraining and instead adjusts synthesized output to recover valid biological estimates with appropriately calibrated uncertainty. Applied to MRI and mIF data, PAMS reduced estimation bias and restored nominal confidence interval coverage. Because it is compatible with existing synthesis pipelines, PAMS offers a practical and rigorous route to statistically and biologically valid use of synthesized images in biomedical imaging research.

  • Open Access

    A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

    by Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey, Pim Cuijpers, Mathias Harrer, Megan T. Jones, Sandeep M. Nayak, Eric C. Strain, Simon N. Vandekar, David B. Yaden, et al.

    3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD). However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release, 6 randomized controlled trials comprising 286 participants are included in the database. All six studies included in the review to date are sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). Our primary model uses inverse-variance random-effects meta-analysis of standardized mean differences on primary outcomes of PTSD. Compared to control conditions, MDMA-assisted therapy (MDMA-AT) showed a greater reduction in PTSD symptoms (Hedges’ g = −0.71). Meta-regressions on dosing variables were explored. Treatment with MDMA-AT as compared to placebo also resulted in higher response (risk ratio [ RR ] = 1.35) and remission ( RR = 2.25) rates. Most studies included in the database had a low risk of bias according to Cochrane guidelines, though these fail to capture pertinent challenges in the field such as expectancy, functional unblinding, potential issues with study conduct, and safety. The current findings were assigned an overall low certainty rating using the GRADE approach. Together, this systematic review and meta-analysis suggests that MDMA-AT results in short-term decreases in PTSD symptoms across studies to date. This living systematic review, meta-analysis, database, and online dashboard ( sypres.io ) will continue to be updated as evidence emerges, providing a valuable, open, and transparent resource for researchers in a rapidly evolving field.

  • Open Access

    Vanderbilt Integrated Community TMS for Opioid Recovery (VICTORY): Study protocol for a randomized, controlled trial of non-invasive brain stimulation to reduce craving in people with opioid use disorder

    by Kathryn Biernacki, Jillian Connolly, Libby Tunison, Kristopher A. Kast, Simon Vandekar, Benson King, Tashley Aouina, Beth Black, Rachel Craig, Jason Ferrell, et al.

    Background: Individuals receiving buprenorphine treatment for opioid use disorder (OUD) remain at high risk for treatment discontinuation and return to opioid use. Transcranial magnetic stimulation (TMS) has shown efficacy in reducing craving and substance use in other substance use disorders, but its application in OUD remains limited and the neural mechanism underlying its therapeutic effects is poorly understood. Determining the feasibility and generalizability of TMS in patients receiving buprenorphine – the most commonly prescribed medication for OUD – is therefore critical. This protocol aims to address these issues in a clinical trial of weekly TMS sessions for OUD. Methods: We will enroll up to 120 individuals with OUD taking buprenorphine in a randomized, single-blind, sham-controlled trial of left dorsolateral prefrontal cortex (DLPFC)-targeted intermittent theta burst stimulation (iTBS). Participants will receive active or sham iTBS weekly (2 sessions of 1800 pulses each applied once per week x 8 weeks, 16 sessions total) with pre- and post-iTBS assessments (10, 12, 20 weeks) of craving, opioid use, and treatment retention. A subset of individuals will undergo optional pre- and post-iTBS neuroimaging. The study will be conducted at an academic medical center and a private outpatient TMS clinic. Aims: Our primary aim is to determine whether 16 sessions of active iTBS applied to the left DLPFC results in reduced craving and opioid use, and higher treatment retention, relative to sham. In a secondary aim, we will also examine whether iTBS-related changes in craving are associated with changes in functional connectivity between the left DLPFC and both the dorsal striatum and anterior cingulate cortex. Discussion: By evaluating the feasibility and efficacy of a weekly TMS protocol that aligns with routine care and focuses on patients maintained on buprenorphine, this study addresses key limitations of prior TMS research in OUD. Furthermore, the inclusion of neuroimaging will help characterize the neural mechanisms underlying TMS-related changes in craving. Trial registration: This clinical trial is registered at ClinicalTrials.Gov; ID NCT07457489 ; date of registration: 03/02/2026.

  • Open Access

    Vanderbilt Integrated Community TMS for Opioid Recovery (VICTORY): Study protocol for a randomized, controlled trial of non-invasive brain stimulation to reduce craving in people with opioid use disorder

    by Kathryn Biernacki, Jillian Connolly, Libby Tunison, Kristopher A. Kast, Simon Vandekar, Benson King, Tashley Aouina, Beth Black, Rachel Craig, Jason Ferrell, et al.

    Background: Individuals receiving buprenorphine treatment for opioid use disorder (OUD) remain at high risk for treatment discontinuation and return to opioid use. Transcranial magnetic stimulation (TMS) has shown efficacy in reducing craving and substance use in other substance use disorders, but its application in OUD remains limited and the neural mechanism underlying its therapeutic effects is poorly understood. Determining the feasibility and generalizability of TMS in patients receiving buprenorphine - the most commonly prescribed medication for OUD - is therefore critical. This protocol aims to address these issues in a clinical trial of weekly TMS sessions for OUD. Methods: We will enroll up to 120 individuals with OUD taking buprenorphine in a randomized, single-blind, sham-controlled trial of left dorsolateral prefrontal cortex (DLPFC)-targeted intermittent theta burst stimulation (iTBS). Participants will receive active or sham iTBS weekly (2 sessions of 1800 pulses each applied once per week x 8 weeks, 16 sessions total) with pre- and post-iTBS assessments (10, 12, 20 weeks) of craving, opioid use, and treatment retention. A subset of individuals will undergo optional pre- and post-iTBS neuroimaging. The study will be conducted at an academic medical center and a private outpatient TMS clinic. Aims: Our primary aim is to determine whether 16 sessions of active iTBS applied to the left DLPFC results in reduced craving and opioid use, and higher treatment retention, relative to sham. In a secondary aim, we will also examine whether iTBS-related changes in craving are associated with changes in functional connectivity between the left DLPFC and both the dorsal striatum and anterior cingulate cortex. Discussion: By evaluating the feasibility and efficacy of a weekly TMS protocol that aligns with routine care and focuses on patients maintained on buprenorphine, this study addresses key limitations of prior TMS research in OUD. Furthermore, the inclusion of neuroimaging will help characterize the neural mechanisms underlying TMS-related changes in craving. Trial registration: This clinical trial is registered at ClinicalTrials.Gov; ID NCT07457489 ; date of registration: 03/02/2026.

  • Open Access

    Accelerated DMN-targeted cTBS improves processing speed deficits in schizophrenia

    by Jillian G. Connolly, Sophia H. Blyth, Gulcan Yildiz, Baxter P. Rogers, Simon Vandekar, Mark A. Halko, Roscoe O. Brady, Heather Burrell Ward

    Cognitive deficits are a leading cause of disability in schizophrenia and are linked to poor functional outcomes. There are no first line treatments for these deficits, and their neural basis is poorly understood. While schizophrenia is associated with widespread cognitive deficits, information processing speed is most profoundly impaired. Processing speed deficits have been associated with hyperconnectivity in the Default Mode Network (DMN). We therefore tested if modulating DMN connectivity with single or multiple sessions of transcranial magnetic stimulation (TMS) applied to an individualized DMN target would affect processing speed. In the first study, 10 individuals with schizophrenia received single TMS sessions and underwent resting-state neuroimaging and processing speed assessment (Brief Assessment of Cognition in Schizophrenia digit symbol coding) acutely before and after each session. These sessions included excitatory (intermittent theta burst stimulation, iTBS); inhibitory (continuous theta burst stimulation, cTBS); and sham stimulation sessions. In the second study, 29 individuals (17 schizophrenia, 12 non-psychosis controls) received 5 accelerated sessions of cTBS with resting-state neuroimaging and processing speed assessment before and after the course of TMS sessions. In the accelerated, multi-session DMN-targeted TMS trial, cTBS improved processing speed in the schizophrenia group ( p = 0.0124). In individuals with schizophrenia, reduction in DMN connectivity was linked to improvement in processing speed ( p = 0.021). These changes were dependent on age, where younger participants experienced greater processing speed improvements than older participants ( p = 0.006). In sum, personalized network targeted TMS may be a novel method for reducing cognitive impairment associated with schizophrenia.

  • Open Access

    Calibration of MRI-based reference intervals to new samples

    by Andrew A. Chen, Jakob Seidlitz, Margaret Gardner, Richard A.I. Bethlehem, Lena Dorfschmidt, Eren Kafadar, Andreana Benitez, Jens H. Jensen, Simon Vandekar, Theodore D. Satterthwaite, et al.

    Reference intervals, defined as intervals containing a new observation with a specified probability relative to reference data, would be clinically useful in assessing brain magnetic resonance imaging (MRI). Brain charts, which are estimates of MRI phenotypes across covariates such as age and sex, can be used to construct reference intervals. However, the reference data used to fit intervals often differ from a new sample in terms of study design, MRI acquisition, and image preprocessing. Application of MRI reference intervals to new samples remains a challenging problem. Here, we propose a new method called reference interval calibration via conFormal prediction (ReForm) that adjusts reference intervals for a new sample. Our method builds on recent work in conformal prediction, which yields intervals with guaranteed coverage for new observations. Through resampling experiments in Lifespan Brain Chart Consortium cortical thickness data, we compare ReFormed reference intervals with refitting intervals, statistical harmonization methods, and model-based adjustment of intervals. Notably for patient privacy concerns, ReForm does not require sharing of reference data. Yet, our empirical results demonstrate that ReForm controls FPR similarly or better than alternative methods that require sharing reference data. Finally, we provide recommendations for practical applications of ReForm and an R package (https://github.com/andy1764/ReForm) for calibrating reference intervals using ReForm.

  • Open Access

    Charting Cervical Spinal Cord Morphometry Across the Lifespan

    by Kurt G. Schilling, Michael E. Kim, Matthew Amandola, Chenyu Gao, Karthik Ramadass, Praitayini Kanakaraj, Sam Bogdanov, Gaurav Rudravaram, Nancy R. Newlin, Derek Archer, et al.

    Spinal cord morphometry provides essential biomarkers of neurological health, but clinical interpretations are confounded by inter-subject variability and a lack of normative references across the full human lifespan. We address this gap by generating the first comprehensive lifespan charts for cervical spinal cord morphometry. We leveraged 30 population-based brain MRI datasets, aggregating 78,269 scans from 41,042 individuals (ages 0–100) whose imaging protocols included cervical cord coverage. To overcome contrast variability, we employed a state-of-the-art contrast-agnostic deep learning segmentation method, extracting cross-sectional area (CSA), anteroposterior (AP) and right–left (RL/transverse), and shape indices (compression ratio, eccentricity, and solidity) from C1 to C7. Normative trajectories were modeled using Generalized Additive Models for Location, Scale, and Shape (GAMLSS). The resulting charts reveal distinct non-linear lifespan changes: rapid growth through childhood and adolescence, peak maturation occurring in early-to-mid adulthood (e.g., mid-30s for CSA), followed by gradual decreases. Significant regional variations along the cervical cord and consistent sex differences (males > females for size metrics) were quantified. Spinal cord trajectories showed strong temporal coupling with brain white matter and brainstem volumes, suggesting integrated CNS development and aging. These lifespan charts provide a robust normative framework, enabling age- and sex-specific centile scoring of individual spinal cord morphometry. This resource offers a critical tool for differentiating typical variation from pathological changes, enhancing the clinical utility of spinal cord MRI in studies of development and neurodegeneration.

  • Open Access

    Publisher Correction: White matter micro- and macrostructure brain charts for the human lifespan

    by Michael E Kim, Chenyu Gao, Karthik Ramadass, Nancy R Newlin, Praitayini Kanakaraj, Sam Bogdanov, Gaurav Rudravaram, Derek Archer, Timothy J Hohman, Angela L Jefferson, et al.

  • Top Cited Papers
    Open Access

    White matter micro- and macrostructure brain charts for the human lifespan

    by Michael E. Kim, Chenyu Gao, Karthik Ramadass, Nancy R. Newlin, Praitayini Kanakaraj, Sam Bogdanov, Gaurav Rudravaram, Derek Archer, Timothy J. Hohman, Angela L. Jefferson, et al.

    The human brain relies on a complex network of connections to function, with white matter acting as the primary communication highway between different brain regions 1,2 . Disruptions in these critical communication pathways are linked to several neurological, psychiatric and developmental disorders 3,4 . Although clinicians have long used standard growth charts to track physical development 5 , with more recent work translating these to whole-brain and grey matter measurements 6–9 , there has been no equivalent reference standard for white matter. Establishing a readily available normative reference is an imperative first step if we hope to utilize these white matter structural biomarkers clinically. Here we present lifespan reference charts for human brain white matter. By processing and standardizing 35,120 brain scans from diverse global studies, we mapped the typical growth, maturation and age-related decline of specific brain pathways from birth to 100 years of age. These reference charts establish a fundamental benchmark for healthy brain development and ageing, allowing researchers and clinicians to quantify how an individual’s brain deviates from typical patterns and highlighting disorder-related alterations. Furthermore, the accompanying open access charts enable the scientific and clinical communities to evaluate new patient and research data against these normative baselines, facilitating future clinical and neuroscience studies.